Date:9/18/2007

cal device manufacturers, and other professional communities to work together and solve problems in a timely, ef.cient and economical way. The company's set of proprietary collaborative technology products fosters the discovery of new treatment plans, more effective surgical techniques, and life-saving medical devices. Syndicom's advanced communication tools let physicians around the world share challenging patient cases and respond immediately to colleagues' questions. At the same time, Syndicom's innovative platform gives medical companies the ability to leverage and extend the knowledge and skills of physicians in the development of new medical technologies and devices. To learn more visit http://www.syndicom.com.

Contacts: Lee Graham Ronald Trahan, APR

(212) 333-4983 Ronald Trahan Associates, Inc.

leegraham@leegraham.biz 508-359-4005, x108

'/>"/>

SOURCE Syndicom Copyright©2007 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3
Related medicine technology :

1. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
2. Materia Licenses Metathesis Catalyst Platform to Eisai
3. Pieris Progresses Development of its Proprietary Biotherapeutics Platform: Successful Demonstration of Dual Targeting With Duocalin(R) Technology
4. Indivumed Study Provides Sound Scientific Basis for a Predictive Drug Test- Platform
5. Abraxis BioScience Presents Pre-Clinical Findings That Support Role of SPARC Expression in Cancer and the Role of the Nanoparticle Albumin Bound (nab) Technology Platform in Targeting the Pathway
6. AVEO Pharmaceuticals Novel Oncology Research Platform and Clinical Pipeline to Be Featured at AACR
7. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
8. Genetic Analysis Systems Enter the Clinical Mainstream
9. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
10. Large Geographic Differences in EpiPen Prescriptions in the U.S., From the Journal of Allergy and Clinical Immunology
11. Sygnis Pharma AG announces date for presentation of clinical results